GEICAM, Spain Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2014
NCT02027376
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

GEICAM (Spanish Breast Cancer Research Group)

Active Ingredients

Drugs in Phase 2 Trials (2)

gemcitabine (gemzar) (1 trial)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (2)

docetaxel (taxotere) (1 trial)

sonidegib (odomzo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4